Novartis (NVS) has discontinued the development of VHB937/lifonebart, an experimental therapy for a fatal nervous system disease known as amyotrophic lateral sclerosis, following a mid-stage trial ...

Novartis (SWX:NOVN) agreed to acquire full rights to Sironax's proprietary brain delivery platform for neurological disease ...

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

On 8, 2026, CNBC reported that Novartis AG (NYSE:NVS) shares fell about 10% after the company said its experimental drug ...

Novartis is acquiring a Sironax platform technology designed to transport a range of drug modalities across the protective ...

The patients had an immune reaction where the body's defenses attacked its own organs, leading to their deaths.

Novartis halted eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died.

The FDA has approved the industry’s very first generic radioligand therapy, known as a radioligand equivalent.  | The FDA has approved the industry’s first radioligand equivalent in Curium’s lutetium ...

Novartis (NVS) on Thursday announced that the European Commission approved its gene therapy. Itvisma (onasemnogene abeparvovec) for children aged two years and older with spinal muscular atrophy, a ...

SAN FRANCISCO — Almost five years after betting big on gene therapy, Novartis' CEO, Vas Narasimhan, said the decision's been a success — but one that hasn't produced therapies as quickly as he's hoped ...

Legend Biotech has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its next phase of growth. Zhang officially took the Legend CEO title on Sept. 15, ...